Methods Of Treatment With Angiopoietin-2 Antibodies

Abstract

The disclosure is directed to methods and uses of antibodies or antigen-binding fragments thereof against Angiopoietin-2 (Ang-2). Specifically, the disclosure is direct to the use of anti-Ang2 antibodies or antigen-binding fragments thereof for treating ischemia. The methods disclosed are useful for reducing microvascular permeability, increasing microvascular perfusion, reducing inflammation in a tissue, and treating or ameliorating diseases associated with ischemia and/or reperfusion injury. The disclosed methods are also useful for protecting solid organ transplant tissue and treating or preventing chronic tissue transplant rejection.

What is claimed is: 
     
         1 .- 5 . (canceled) 
     
     
         6 . A method for protecting a solid organ transplant tissue, comprising administering an effective amount of an anti-Ang2 antibody or antigen-binding fragment thereof to an allograft. 
     
     
         7 .- 11 . (canceled) 
     
     
         12 . A method for treating or ameliorating myocardial ischemia, comprising administering a therapeutically effective amount of an anti-Ang2 antibody or antigen-binding fragment thereof to a subject in need thereof. 
     
     
         13 . A method for treating an IRI-induced inflammatory response in a subject comprising administering a therapeutically effective amount of an anti-Ang2 antibody or antigen-binding fragment thereof to the subject in need thereof. 
     
     
         14 . (canceled) 
     
     
         15 . The method of  claim 6 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof neutralizes Ang-2. 
     
     
         16 . The method of  claim 6 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof preferentially binds Ang-2 over Ang-1. 
     
     
         17 . The method of  claim 6 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof is an antibody that binds to and neutralizes Ang-2, but does not bind to Ang-1. 
     
     
         18 .- 37 . (canceled) 
     
     
         38 . The method of  claim 12 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof neutralizes Ang-2. 
     
     
         39 . The method of  claim 12 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof preferentially binds Ang-2 over Ang-1. 
     
     
         40 . The method of  claim 12 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof is an antibody that binds to and neutralizes Ang-2, but does not bind to Ang-1. 
     
     
         41 . The method of  claim 13 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof neutralizes Ang-2. 
     
     
         42 . The method of  claim 13 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof preferentially binds Ang-2 over Ang-1. 
     
     
         43 . The method of  claim 13 , wherein the anti-Ang2 antibody or antigen-binding fragment thereof is an antibody that binds to and neutralizes Ang-2, but does not bind to Ang-1.